Bristol Reyataz Dosing For Renally-Impaired Patients Will Be Phase IV Study
FDA is requesting that Bristol-Myers Squibb determine appropriate Reyataz dosing for patients with renal impairment in a Phase IV study
You may also be interested in...
Bristol-Myers Squibb will make Reyataz (atazanavir) available in July following the June 20 approval of the HIV treatment
The favorable lipid profile of Bristol-Myers Squibb's protease inhibitor Reyataz offers HIV patients a clinical benefit over other protease inhibitors, FDA's Antiviral Drugs Advisory Committee agreed May 14
Bristol-Myers Squibb's protease inhibitor Reyataz is on track for a June approval with a broad label recommendation following a positive advisory committee review May 13